Register for OBR daily




To find out more about a company click on the company name to see a brief profile.

OBR Finance Top 5 Winners

MRTX $7.17 0.9692 +15.63%
CCXI $5.74 0.4900 +9.33%
PPHM $0.45 0.0370 +8.87%
JUNO $32.20 2.5500 +8.60%
KITE $59.68 4.6950 +8.54%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

OBR Finance Top 5 Losers

NKTR $16.74 -1.2900 -7.15%
BLRX $1.18 -0.0500 -4.07%
UTHR $121.65 -3.9200 -3.12%
KBIO $3.44 -0.1100 -3.10%
GALT $2.45 -0.0739 -2.93%

Quotes Are Updated Every 20 Minutes. Companies with a Market Cap of less than $50M are not included.

Archived News Headlines

We have been archiving all OBR daily news stories since March 2008. Use the box below to search our archives for specific articles and content.

Please note: we do not "host" news articles on our website. When a media source removes an article from their website the link becomes inactive, and you will only be able to see the date, title, first sentence and media source that published the article.

<< First | < Prev | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | Next > | Last >>

No, Apple's New AirPods Won't Give You Cancer, Experts Say

(Los Angeles Times/Science Now blog) Sept 8, 2016 - The technology analysts have been calling Apple's decision to eliminate the earphone jack on its new iPhone 7 a risky business move.
read article (free registration required) 



Patients and Physicians at Hematology-Oncology Associates of Central New York Launch National Cancer Advocacy Group Chapter

(COA) Sept 8, 2016 - Today patients and leaders from the Hematology-Oncology Associates of Central New York (HOACNY) in East Syracuse, NY came together to launch a local chapter of the COA Patient Advocacy Network (CPAN), the national patient network of the Community Oncology Alliance (COA).
read press release 



Fate Therapeutics and Memorial Sloan Kettering Cancer Center Launch Partnership for Development of Off-the-Shelf T-Cell Immunotherapies

(Fate Therapeutics) Sept 7, 2016 - Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today a partnership with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines.
read corporate press release 



Cancer Survivorship Is On The Rise -- And That's Both Good News And Bad

(Forbes) Sept 9, 2016 - The Stand Up to Cancer telethon is tonight, and the hour-long TV event promises to offer a mix of inspiring cancer survivors and celebrities like Jon Hamm and Kristen Wiig hailing the accomplishments of the 8-year-old fundraising outfit, which has hauled in $370 million for oncology research so far.
read article 



Tyler Jacks, Cancer Moonshot Panel Co-Chair, Discusses Roadmap

(Xconomy National) Sept 9, 2016 - This week, a panel of 28 scientists presented the National Cancer Institute's National Cancer Advisory Board a set of recommendations and national priorities for basic research, clinical trial practice, and drug development. In an interview with Xconomy, panel co-chair Tyler Jacks acknowledged the recommendations were broad, with many details yet to be worked out.
read article 



Insurance Status Impacts Survival In Men With Testicular Cancer

(Dana-Farber Cancer Institute) Sept 8, 2016 - Men with testicular cancer who were uninsured or on Medicaid had a higher risk of death from what is normally a curable disease than insured patients, a new study found.
read press release 



Sugar Transforms a Traditional Chinese Medicine Into a Cruise Missile

(Johns Hopkins Medicine) Sept 7, 2016 - Anticancer compound becomes more soluble and selective after glucose is attached.
read press release 



Experimental Drug Could Stop Melanoma, Other Cancers, Research Suggests

(UV Health System) Sept 6, 2016 - An experimental cancer drug works differently than intended and shows significant promise for stopping melanoma and possibly other forms of cancer, research from the School of Medicine suggests.
read press release 



Tamoxifen Resistance Linked to High Estrogen Levels In Utero

(GUMC) Sept 8, 2016 - An animal study suggests that resistance to tamoxifen therapy in some estrogen receptor positive breast cancers may originate from in utero exposure to endocrine disrupting chemicals.
read press release 



Case for Liquid Biopsies Builds in Advanced Lung Cancer

(Penn Medicine) Sept 9, 2016 - For patients with advanced lung cancer, a non-invasive liquid biopsy may be a more effective and suitable alternative to the gold standard tissue biopsy to detect clinically relevant mutations and help guide their course of treatment, suggests a new study.
read press release 



2016 Symposium Highlights Notable Research Advances in Palliative Care

(ASCO/2016 Palliative Care in Oncology Symposium) Sept 8, 2016 - Seven studies investigating key issues in palliative care will be presented at the 2016 Palliative Care in Oncology Symposium, taking place September 9-10, at the San Francisco Marriott Marquis.
read press release 



A Map To Help Cancer Doctors Find Their Way

(NPR/Shots blog) Sept 9, 2016 - What if doctors could call up a computerized map that would show them how a case of cancer is likely to progress?
read article 



Puerto Ricans, Mexicans, Cubans Lead Latinos in Breast Cancer Death Rates

(NBC News) Sept 8, 2016 - Puerto Ricans, Mexicans, and Cubans have the highest breast cancer mortality rate among Hispanics, according to a study released Thursday by the Avon Foundation for Women.
read article 



U.S. Health Law Faces Critical Year

(Wall Street Journal) Sept 7, 2016 - Significant spikes in premiums, insurer dropouts and persistently low enrollment numbers are combining to make this fall’s sign-up period a crossroads for the Obama administration’s signature health law.
read article (paid subscription required) 



Retrophin Kidney Drug Exceeds Expectations In Trial, Shares Jump

(Reuters) Sept 7, 2016 - Retrophin Inc said its drug for a rare kidney disorder, which has no specific treatment, was found safe and effective in a mid-stage study, sending the company's shares soaring as much as 44 percent on Wednesday.
read article 



GW Pharmaceuticals Jumps on Report It May Be Acquisition Target

(Bloomberg) Sept 7, 2016 - GW Pharmaceuticals Plc jumped after Reuters reported that the company had hired Morgan Stanley as an adviser after being approached by several drugmakers interested in an acquisition.
read article 



Express Scripts Urges Narrower Coverage of Anti-Inflammatory Drugs

(New York Times) Sept 8, 2016 - Seeking to force drug price competition in an expensive category, the company wants insurers to cover fewer anti-inflammatory drugs, at least as a first-line treatment.
read article 



ASCO-AACI Best Practices in Cancer Clinical Trials Findings Published in JCO

(ASCO in Action) Sept 6, 2016 - Findings from ASCO's collaborative effort with the American Association of Cancer Institutes (AACI), the ASCO-AACI Best Practices in Cancer Clinical Trials Initiative, were published recently in the Journal of Clinical Oncology (JCO).
read article 



New Articles Highlight the Potentials of Patient Reported Outcome Tools and Measurements

(ASCO in Action) Sept 6, 2016 - Two studies on Patient Reported Outcome (PRO) measures from ASCO's 2016 Quality Care Symposium (QCS) are a part of an upcoming Journal of Oncology Practice QCS Specials Series.
read article 



ASCO Applauds Bold Recommendations from Cancer Moonshot Blue Ribbon Panel

(ASCO) Sept 7, 2016 - ASCO commends the Cancer Moonshot Initiative Blue Ribbon Panel for its ambitious recommendations to accelerate progress against cancer.
read press release 



AACR Embraces Cancer Moonshot Blue Ribbon Panel's Recommendations

(AACR) Sept 7, 2016 - The American Association for Cancer Research (AACR) expresses its unequivocal support for the 10 recommendations that were outlined today by the Cancer Moonshot Blue Ribbon Panel at the National Cancer Institute's (NCI) National Cancer Advisory Board (NCAB) Meeting.
read press release 



Veracyte Achieves Major Medicare Coverage Milestone for the Percepta® Classifier to Improve Lung Cancer Diagnosis

(Yahoo! Finance) Sept 8, 2016 - Veracyte, Inc. today announced that Noridian Healthcare Solutions, the nation's largest Medicare Administrative Contractor (MAC), has issued a draft local coverage determination (LCD) for the Percepta Bronchial Genomic Classifier. When finalized, this LCD will enable coverage for over 30 million – or more than half – of the Medicare beneficiaries in the United States.
read article 



Cancer Cures Could Already Exist In Big Data

(Fast Company) Sept 7, 2016 - "Reuse, and recycle" is a famous saying of the environmental movement, but cancer researchers might learn a thing or two from that mantra as well.
read article 



BRIEF - Clovis Oncology

(Reuters) Sept 8, 2016 - FDA has notified the company it is not currently planning to hold an advisory committee meeting to discuss Rucaparib.
read article 



A New Cancer Immunotherapy Leads to Remissions

(TIME) Sept 8, 2016 - In a small new study published in Science Translational Medicine, researchers who are pioneering an immune-based treatment for cancer report encouraging results among people with otherwise untreatable non-Hodgkin lymphoma, a blood cancer.
read article